OmniAb Inc OABI
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
OmniAb to Host Investor & Analyst Day on October 6, 2026
-
OmniAb to Participate in Upcoming Investor Conferences
-
OmniAb Enters Collaboration, License Agreement with Eli Lilly
-
OmniAb Raises 2026 Financial Guidance
-
OmniAb Announces Global Collaboration and License Agreement for Ion Channel Program with Eli Lilly & Company
-
OmniAb Reports Second Quarter 2026 Financial Results and Business Highlights
-
OmniAb to Report Second Quarter 2026 Financial Results on August 6
-
OmniAb Names Amechi Nwachuku Chief Operating Officer
Trading Information
- Previous Close Price
- —
- Day Range
- —–—
- 52-Week Range
- —–—
- Bid/Ask
- — / —
- Shares Outstanding
- 145.39M
- Market Cap
- —
- Volume/Avg
- — / —
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 16.21
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
OmniAb Inc licenses discovery research technology to pharmaceutical and biotech companies and academic institutions to enable the discovery of next-generation therapeutics. Its technology platform creates and screens diverse antibody repertoires and is designed to quickly identify optimal antibodies and other target-binding proteins for its partners’ drug development efforts. At the heart of the OmniAb platform is what it calls Biological Intelligence, which powers the immune systems of proprietary, engineered transgenic animals to create optimized antibody candidates for human therapeutics.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 89
- Website
- https://www.omniab.com
Valuation
|
Metric
|
OABI
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 2.79 |
Price/Sales | 16.21 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
OABI
|
|---|---|
Quick Ratio | 4.53 |
Current Ratio | 4.80 |
Interest Coverage | — |
Quick Ratio
OABI
Profitability
|
Metric
|
OABI
|
|---|---|
Return on Assets (Normalized) | −10.28% |
Return on Equity (Normalized) | −11.53% |
Return on Invested Capital (Normalized) | −11.59% |
Return on Assets
OABI
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|N$q#sf | LOCK|^F^rx | $128B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|&$L&w? | LOCK|yQ^mh | $76B | |||
| Moderna Inc
MRNA
| LOCK|^j@&%sM | LOCK|mp | $75B | |||
| argenx SE ADR
ARGX
| LOCK|s@%Xdvq | LOCK|%P | $60B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|^#pWfw | LOCK|!Cd | $44B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|B?z&s$ | LOCK|#@KM | $31B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|Z&pFhgsh | LOCK|@tmvq | $26B | |||
| BioNTech SE ADR
BNTX
| LOCK|Js>mv% | LOCK|%z | $24B | |||
| Incyte Corp
INCY
| LOCK|Sy^%!? | LOCK|hS | $24B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|HN%J>%K | LOCK|v%Z | $15B |
United States